Smad4 inactivation predicts for worse prognosis and response To fluorouracil-based treatment in colorectal cancer

Journal of Clinical Pathology

Volumn 68, Issue 5, 2015, Pages 341-345

  Kozak, Margaret M ^a   Von Eyben, Rie ^a   Pai, Jonathan ^a   Vossler, Stephen R ^a   Limaye, Maneesha ^a   Jayachandran, Priya ^a   Anderson, Eric M ^a   Shaffer, Jenny L ^a   Longacre, Teri ^b   Pai, Reetesh K ^c   Koong, Albert C ^a   Chang, Daniel T ^a  

^a STANFORD CANCER INSTITUTE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FLUOROURACIL; SMAD4 PROTEIN; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; SMAD4 PROTEIN, HUMAN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; COLON METASTASIS; COLON RESECTION; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SURVIVAL PREDICTION; TISSUE MICROARRAY; TREATMENT RESPONSE; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; CHEMISTRY; COLORECTAL NEOPLASMS; DISEASE COURSE; DOWN REGULATION; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TIME; TREATMENT OUTCOME; TUMOR RECURRENCE; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOWN-REGULATION; FEMALE; FLUOROURACIL; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SMAD4 PROTEIN; TIME FACTORS; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84928107720     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2014-202660     Document Type: Article

References (19)

1. Saridaki Z, Tzardi M, Sfakianaki M, et al. BRAFV600E mutation analysis in patients with metastatic colorectal cancer (mCRC) in daily clinical practice: correlations with clinical characteristics, and its impact on patients' outcome. PLoS ONE 2013;8:e84604.
2. Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487:330-7.
3. Ogunbiyi OA, Goodfellow PJ, Herfarth K, et al. Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator. J Clin Oncol 1998;16:427-33.
4. Jen J, Kim H, Piantadosi S, et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 1994;331:213-21.
5. Lanza G, Matteuzzi M, Gafa R, et al. Chromosome 18q allelic loss and prognosis in stage II and III colon cancer. Int J Cancer 1998;79:390-5.
6. Miyaki M, Iijima T, Konishi M, et al. Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis. Oncogene 1999;18:3098-103.
7. Calon A, Espinet E, Palomo-Ponce S, et al. Dependency of colorectal cancer on a TGF-beta-driven program in stromal cells for metastasis initiation. Cancer Cell 2012;22:571-84.
8. Akhurst RJ, Hata A. Targeting the TGFbeta signalling pathway in disease. Nat Rev Drug Discov. 2012;11:790-811.
9. Schmierer B, Hill CS. TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility. Nat Rev Mol Cell Biol 2007;8:970-82.
10. Massague J. TGFbeta signalling in context. Nat Rev Mol Cell Biol 2012;13:616-30.
11. Ahn BK, Jang SH, Paik SS, et al. Smad4 may help to identify a subset of colorectal cancer patients with early recurrence after curative therapy. Hepatogastroenterology 2011;58:1933-6.
12. Alazzouzi H, Alhopuro P, Salovaara R, et al. SMAD4 as a prognostic marker in colorectal cancer. Clin Cancer Res 2005;11:2606-11.
13. Miyaki M, Kuroki T. Role of Smad4 (DPC4) inactivation in human cancer. Biochem Biophys Res Commun 2003;306:799-804.
14. Roth AD, Delorenzi M, Tejpar S, et al. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. J Natl Cancer Inst 2012;104:1635-46.
15. Weiss JM, Schumacher J, Allen GO, et al. Adjuvant chemotherapy for stage II right-sided and left-sided colon cancer: analysis of SEER-medicare data. Ann Surg Oncol 2014;21:1781-91.
16. O'Connor ES, Greenblatt DY, LoConte NK, et al. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol 2011;29:3381-8.
17. Papageorgis P, Cheng K, Ozturk S, et al. Smad4 inactivation promotes malignancy and drug resistance of colon cancer. Cancer Res 2011;71:998-1008.
18. Alhopuro P, Alazzouzi H, Sammalkorpi H, et al. SMAD4 levels and response to 5-fluorouracil in colorectal cancer. Clin Cancer Res 2005;11:6311-16.
19. Zhang B, Zhang B, Chen X, et al. Loss of Smad4 in colorectal cancer induces resistance to 5-fluorouracil through activating Akt pathway. Br J Cancer 2014;110:946-57.